Clinical Trials Related to Hodgkin Lymphoma

Related studies linked through entity extraction aliases.

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Status: COMPLETED
Phase: PHASE2

Auto Stem Cell Transplant for Lymphoma Patients

Status: RECRUITING
Phase: PHASE2

Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma

Status: TERMINATED
Phase: PHASE2

⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma

Status: COMPLETED
Phase: PHASE1

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Status: COMPLETED
Phase: PHASE2

Familial Investigations of Childhood Cancer Predisposition

Status: RECRUITING
Phase: N/A

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

Status: COMPLETED
Phase: PHASE1

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Status: TERMINATED
Phase: PHASE2

Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

Status: COMPLETED
Phase: PHASE1

Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery

Status: COMPLETED
Phase: NA

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Status: COMPLETED
Phase: PHASE1

Genetic Study of Families With High Frequency of Hodgkin Lymphoma

Status: COMPLETED
Phase: N/A

Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool

Status: UNKNOWN
Phase: N/A

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas

Status: TERMINATED
Phase: PHASE2

UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

Status: COMPLETED
Phase: PHASE2

Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)

Status: COMPLETED
Phase: PHASE3

Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Status: COMPLETED
Phase: PHASE1

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Status: TERMINATED
Phase: PHASE2

Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma

Status: TERMINATED
Phase: EARLY_PHASE1